📰 In Process Research News
In Process Research News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from In Process Research. Real-time updates on events, politics, business and more.
April 25, 2024
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for...
April 12, 2024
Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. investors concerning the Company’s possible violations of federal securities laws. On April 4, 2024, AbbVie...
April 5, 2024
Estimated First Quarter 2024 Acquired In-Process Research and Development Charges Eli Lilly and Company currently expects that its reported financial results...
February 29, 2024
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the...
June 28, 2023
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well...
June 28, 2023
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all dosesA Phase 2 study of RVT-3101 in Crohn’s ...
May 8, 2023
First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders... | May 8, 2023
April 11, 2023
Estimated First Quarter 2023 Acquired In-Process Research and Development Charges Eli Lilly and Company currently expects that its reported financial results... | April 11, 2023
March 23, 2023
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term... | March 23, 2023
March 23, 2023
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody against SARS-CoV...